(Reuters) -Johnson & Johnson ( JNJ ) said on Friday its experimental psoriasis drug helped patients achieve clear or almost clear skin in a late-stage study.

The once-daily oral drug, icotrokinra, was tested in patients 12 years and older with at least moderate plaque psoriasis affecting "high-impact" areas, including the scalp and genitals.

The immune-mediated condition is characterized by thick, scaly patches called plaques on the skin.